Fusion proteins and use thereof for preparing vaccines

US10766930B2 · kind B2 · utility

Assignees

• UNIVERSITÉ DE TOURS · FR
• Centre Hospitalier Regional Et Universitaire De Brest · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

• Christophe Hourioux · La Riche, FR
• Romuald Patient · La Riche, FR
• Elodie Beaumont · La Riche, FR
• Philippe Roingeard · La Riche, FR

Key dates

• Filing date: Jun 16, 2017
• Grant date: Sep 8, 2020
• Expiry date: Jun 16, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An immunogenic fusion protein includes at least the following two peptides a) —on the C-terminal side, a first peptide constituted of: —the amino acid sequence of the protein S or the protein M of a human hepatitis B virus (HBV) isolate, which protein S or protein M is optionally deleted at the N-terminal end thereof, and b) —on the N-terminal side, a second peptide constituted of: —the sequence of amino acids of at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate selected from the envelope protein E or a fusion peptide including the envelope protein E and the protein prM.